Talon Therapeutics, Inc. is a California-based biopharmaceutical company. The Company is engaged in developing and commercializing new and differentiated cancer therapies designed to improves and enable current standards of care. The Company's two product candidates target big markets. The Company is developing Marqibo for the treatment of acute lymphoblastic leukemia and other bloods cancers including lymphoma. The Company is also developing menadione topical lotion, a first-in-class compound, for the potential prevention and/or treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The Company, as of December 31, 2011, had rights to the product candidates in various stages of development.